Biotinylated Human LDLR Protein
Catalog No: LDLR-HB002
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human LDLR Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Ala22-Arg788 (UniProt accession: P01130-1).
Product Details
- Molecular Aliases
- LDLR; FHC; LDL R; LDL receptor; LDLCQ2; FH
- Protein Length
- Ala22-Arg788
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 87.6 kDa, Due to glycosylation, the protein migrates to 120-140 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human LDLR on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human LDLR is greater than 95% as determined by SEC-HPLC.
Biotinylated Human LDLR, His Tag immobilized on CM5 Chip can bind Human PCSK9, His Tag with an affinity constant of 0.23 nM as determined in SPR assay (Biacore T200).
Background
The low density lipoprotein receptor (LDLR) is the founding member of the LDL R family of widely expressed cell surface scavenger receptors. It is a cell-surface receptor that recognizes the apoprotein B100 which is embedded in the phospholipid outer layer of LDL particles.
References
- Al-Allaf F A, Coutelle C, Waddington S N, et al. LDLR-Gene therapy for familial hypercholesterolaemia: Problems, progress, and perspectives[J]. International Archives of Medicine, 2010, 3(1):36.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.